Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αPDL1 in ovarian cancer

Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αPDL1 in ovarian cancer

Abstract Ovarian cancer is resistant to immune checkpoint blockade (ICB) treatment. Combination of targeted therapy and immunotherapy is a promising strategy for ovarian cancer treatment benefit from an improved immune microenvironment. In this study, Clinical Proteomic Tumor Analysis Consortium (CP...

Full description

Bibliographic Details
Main Authors:	Shourong Wang, Yao Liu, Huimin Xiao, Zhongshao Chen, Xiaohang Yang, Jingjing Yin, Yingwei Li, Cunzhong Yuan, Shi Yan, Gang Chen, Qinglei Gao, Beihua Kong, Chaoyang Sun, Kun Song
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-11-01
Series:	Cell Death and Disease
Online Access:	https://doi.org/10.1038/s41419-023-06301-1

Similar Items

The splicing factor SF3B4 drives proliferation and invasion in cervical cancer by regulating SPAG5
by: Yingwei Li, et al.
Published: (2022-07-01)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
by: Tyler Curiel, et al.
Published: (2023-02-01)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
by: Janina Świderska, et al.
Published: (2021-12-01)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
by: Xiaoguang Qi, et al.
Published: (2020-06-01)

Lanosterol synthase deficiency promotes tumor progression by orchestrating PDL1‐dependent tumor immunosuppressive microenvironment
by: Yuan Gao, et al.
Published: (2024-04-01)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
by: Huan Wu, et al.
Published: (2019-12-01)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
by: Huan Wu, et al.
Published: (2020-03-01)

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
by: Yi Huang, et al.
Published: (2024-12-01)

Pyroptosis-related gene expression patterns and corresponding tumor microenvironment infiltration characterization in ovarian cancer
by: Jinhui Liu, et al.
Published: (2022-01-01)

Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy
by: Yundi Chen, et al.
Published: (2022-03-01)

Circ_0001946 Promotes the Development of Acute Myeloid Leukemia by Upregulating PDL1
by: Guohui Li, et al.
Published: (2023-08-01)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
by: Mina Fazel, et al.
Published: (2023-03-01)

957 The ATR-inhibitor ceralasertib modulates the tumor microenvironment and improves the effect of anti-PDL1 by activating type I IFN pathway
by: Dmitry Gabrilovich, et al.
Published: (2023-11-01)

Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment
by: Muhammad Joan Ailia, et al.
Published: (2023-03-01)

C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer
by: Chen Zhang, et al.
Published: (2023-12-01)

Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1
by: Irene Cattaneo, et al.
Published: (2024-02-01)

Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction
by: Sachin P. Patil, et al.
Published: (2022-05-01)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
by: Fereshteh Ameli, et al.
Published: (2022-08-01)

Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo
by: Bo Zhou, et al.
Published: (2019-11-01)

A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer
by: Jiani Yang, et al.
Published: (2023-09-01)

The Presence of PDL-1 on CD8+ Lymphocytes Is Linked to Survival in Neonatal Sepsis
by: Lyudmila L. Akhmaltdinova, et al.
Published: (2022-08-01)

What role does PDL1 play in EMT changes in tumors and fibrosis?
by: Yun-Chao Zhang, et al.
Published: (2023-08-01)

Evaluation of PDL-1 Protein Expression in Tumor Tissues of Patients with Gasteric Cancer
by: Mohammad Abbasi, et al.
Published: (2022-12-01)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
by: Liting Sun, et al.
Published: (2023-04-01)

Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
by: Kunpeng Luo, et al.
Published: (2022-11-01)

Role of PD1/PDL1 pathway, and TH17 and treg cells in maternal tolerance to the fetus
by: Sudipta Tripathi, et al.
Published: (2015-02-01)

A targeted siRNA‐loaded PDL1‐exosome and functional evaluation against lung cancer
by: Xianbin Lin, et al.
Published: (2022-06-01)

Correlation of PDL-1 Expression with Tumour Budding and Tumour Infiltrating Lymphocytes in Colorectal Cancers
by: Tejasvita Singh, et al.
Published: (2023-07-01)

PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
by: Samaresh Sau, et al.
Published: (2019-02-01)

Structure-based virtual screening for PDL1 dimerizers: Evaluating generic scoring functions
by: Viet-Khoa Tran-Nguyen, et al.
Published: (2022-01-01)

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
by: Maria Gato-Cañas, et al.
Published: (2017-08-01)

Multiomics characterization of pyroptosis in the tumor microenvironment and therapeutic relevance in metastatic melanoma
by: Wenqiong Chen, et al.
Published: (2024-01-01)

CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
by: Sophia Fotiou Magkouta, et al.
Published: (2021-05-01)

Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4
by: Gaurav Kumar, et al.
Published: (2021-01-01)

Immunotherapy using PD‑1/PDL-1 inhibitors in triple‑negative breast cancer: a systematic review
by: Dione Tavares, et al.
Published: (2021-12-01)

Is a triggering role or a causative role of PD-1/PDL-1 inhibitors in the development of paraneoplastic dermatomyositis?
by: Michela Starace, et al.
Published: (2022-07-01)

Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective
by: Muhammad Khan, et al.
Published: (2022-12-01)

1509-D Dysgerminoma ovarian germ cell tumours present high expressions of PDL-1 that associated with high tumour infiltrating lymphocytes and good patient prognosis
by: Kholoud Alwosaibai
Published: (2023-11-01)

Microbe-Mediated Activation of Toll-like Receptor 2 Drives PDL1 Expression in HNSCC
by: Jacqueline E Mann, et al.
Published: (2021-09-01)

PDL1 and molecular biomarkers expression in non-small cell lung cancer in Tunisian patients
by: Yoldez Houcine, et al.
Published: (2023-11-01)